ISBN 978-2-08-080052-7
10.3389/fendo.2021.721135 Summary Keywords lymphedema, GLP-1R agonists, GLP-1R agonist, GLP-1RAs, cancer-related lymphedema, Ozempic, semaglutide, liraglutide Citation Brown S, Tadros AB, Montagna G, Bell T, Crowley F, Gallagher EJ and Dayan JH (2024) Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND)
' , , , ', ,
The aggregation of these proteins impairs neuronal function by disrupting cellular balance and inducing toxicity
Payer and Policy Perspectives From the insurer viewpoint, ePA offers mixed implications
The soft tissue over the lower back and hip has a generous fat pad and tends to be less sensitive